A clinical trial studying bariatric surgery as a radical treatment for type 2 diabetes has commenced in Europe:
Instead, investigators have found, bariatric surgery, independent of weight loss, alters metabolic factors such as the hunger-regulating peptide hormone ghrelin (as a result of decreased gastric mass). In addition, bariatric surgery results in increases in peptide YY which has an effect on satiety, and GLP-1, which affects gastric motility and beta-cell mass.
Related posts:
- Bariatric surgery and fatality rates
- $71,000 for 300 bariatric surgeries on Medicare patients
- Adoption on condition of gastric bypass surgery
- Pre-operative beta-blocker dogma
- Diabetes and bariatric surgery
- Stomach surgery
- Minimally invasive surgery via the vagina
KevinMD.com on Facebook
Comments on this entry are closed.